A first-in-class female fertility treatment
-
Non-hormonal
Effective for women who are unresponsive, or low responders, to standard hormone therapy
-
Effective
Notify has demonstrated successful proof-of-concept of efficacy in rodents and ex-vivo utilizing patient samples
-
Controlled
Notify does not impact the body’s natural internal competition – reducing risks associated with carrying multiple pregnancies at once. Preliminary toxicology studies show no safety concerns
What we do
Notify Therapeutics focuses on the initial ovarian follicle development, in the hormone-independent phase, to help infertile women that do not benefit from today’s standard hormone treatment.
Meet the team
Teamwork is crucial at Notify Therapeutics. By collaborating, we leverage diverse skills, create a positive work environment, tackle projects efficiently, and promote growth. It's the foundation of our success.
“There is no doubt that the ‘holy grail’ in infertility infertility remains being able to generate good quality quality eggs in women with low ovarian reserves who who do not respond adequately to established treatment”
— Nick Macklon, Professor of Obstetrics & Gynecology Group Medical Director London Women's Clinic